Dyne Therapeutics, Inc. (DYN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -536.96M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 445.82M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-536.96M | (m) | (m) | $445.82M | (m) | (m) |
| 2026-03-31 | $-471.09M | (m) | (m) | $392.77M | (m) | (m) |
| 2025-12-31 | $-468.18M | (m) | (m) | $398.33M | (m) | (m) |
| 2025-09-30 | $-449.16M | (m) | (m) | $384.71M | (m) | (m) |
| 2025-06-30 | $-440.93M | (m) | (m) | $380.29M | (m) | (m) |
| 2025-03-31 | $-397.10M | (m) | (m) | $343.31M | (m) | (m) |
| 2024-12-31 | $-343.89M | (m) | (m) | $281.41M | (m) | (m) |
| 2024-09-30 | $-314.47M | (m) | (m) | $258.44M | (m) | (m) |
| 2024-06-30 | $-271.08M | (m) | (m) | $220.90M | (m) | (m) |
| 2024-03-31 | $-265.86M | (m) | (m) | $217.76M | (m) | (m) |
| 2023-12-31 | $-242.16M | (m) | (m) | $210.76M | (m) | (m) |
| 2023-09-30 | $-214.62M | (m) | (m) | $185.11M | (m) | (m) |
| 2023-06-30 | $-194.63M | (m) | (m) | $164.53M | (m) | (m) |
| 2023-03-31 | $-180.64M | (m) | (m) | $152.06M | (m) | (m) |
| 2022-12-31 | $-170.96M | (m) | (m) | $142.76M | (m) | (m) |
| 2022-09-30 | $-182.78M | (m) | (m) | $151.87M | (m) | (m) |
| 2022-06-30 | $-183.26M | (m) | (m) | $153.71M | (m) | (m) |
| 2022-03-31 | $-160.67M | (m) | (m) | $130.92M | (m) | (m) |
| 2021-12-31 | $-150.03M | (m) | (m) | $121.31M | (m) | (m) |
| 2021-09-30 | $-126.67M | (m) | (m) | $101.11M | (m) | (m) |
| 2021-06-30 | $-97.42M | (m) | (m) | $74.27M | (m) | (m) |
| 2021-03-31 | $-75.93M | (m) | (m) | $57.74M | (m) | (m) |
| 2020-12-31 | $-58.65M | (m) | (m) | $45.20M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-13.83M | (m) | (m) | $11.04M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |